Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies

30 Jul 2025

Abstract excerpt

ABSTRACT: TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most aggressive and chemotherapy-refractory myeloid neoplasms, with a median overall survival of <6 months. An enormous unmet need exists to develop novel therapeutic strategies, and understand resistance mechanisms to suboptimal existing therapies for this disease. In 2 parallel, phase 2 clinical trials that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40737597
DOI: 10.1182/blood.2025028803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignanciesPMID 40737597Read ↗

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Semantic proximity Read ↗

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.Semantic proximity Read ↗

The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.Semantic proximity Read ↗

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.Semantic proximity Read ↗

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.Semantic proximity Read ↗

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.Semantic proximity Read ↗

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemiaSemantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].Semantic proximity Read ↗

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Multi-level systems analysis identifies XPO1 as a druggable target linked to NFκB activation, proliferation, tumor clonality and long-term survival in Adult T-cell LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.